TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
Brief Summary: A single-blind (investigator-blinded), randomized, parallel group, single center study to evaluate the tolerability and efficacy of combination therapy with Duac Gel / 0.1% Tazorac Cream and Acanya Gel / 0.1% Tazorac Cream for the treatment of facial acne vulgaris.


Options:
A: Arm Label: Duac™Once Daily Gel; Type: EXPERIMENTAL; Interventions: Drug: 1% clindamycin phosphate gel | Arm Label: 1% clindamycin phosphate gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duac™Once Daily Gel | Intervention Type: DRUG; Name: Duac™Once Daily Gel; Assigned to Arm(s): 1% clindamycin phosphate gel | Intervention Type: DRUG; Name: 1% clindamycin phosphate gel; Assigned to Arm(s): Duac™Once Daily Gel
B: Arm Label: Duac & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene | Arm Label: Acanya & taz; Type: ACTIVE_COMPARATOR; Interventions: Drug: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene | Intervention Type: DRUG; Name: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene; Assigned to Arm(s): Duac & taz | Intervention Type: DRUG; Name: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene; Assigned to Arm(s): Acanya & taz
C: Arm Label: Part 1: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 1: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Arm Label: Part 2: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 2: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: ABPO Forte Gel; Assigned to Arm(s): Part 1: ABPO Forte Gel, Part 2: ABPO Forte Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Part 1: ABPO Forte Vehicle Gel, Part 2: ABPO Forte Vehicle Gel
D: Arm Label: CD0271 0.3% /CD1579 2.5% Gel; Type: EXPERIMENTAL; Interventions: Drug: CD0271 0.3% / CD1579 2.5% | Arm Label: CD0271 0.1% / CD1579 2.5%; Type: ACTIVE_COMPARATOR; Interventions: Drug: CD0271 0.1% / CD1579 2.5% | Arm Label: Topical Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical Gel Vehicle | Intervention Type: DRUG; Name: CD0271 0.3% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.3% /CD1579 2.5% Gel | Intervention Type: DRUG; Name: CD0271 0.1% / CD1579 2.5%; Assigned to Arm(s): CD0271 0.1% / CD1579 2.5% | Intervention Type: DRUG; Name: Topical Gel Vehicle; Assigned to Arm(s): Topical Gel Vehicle

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: APCAP - Activated Protein C in Severe Acute Pancreatitis: A Double-blind Randomized Human Pilot Trial
Brief Summary: Activated protein C (APC)has been shown to reduce mortality in severe sepsis(Bernard et al. 2001b). The clinical picture of severe acute pancreatitis (AP) is similar to that of sepsis. The investigators conducted a randomised double-blinded placebo-controlled pilot study in AP patients (16+16) with the same dose of APC that has been proven to be efficacious and safe in septic patients.

The aim of the study is to investigate whether the APC replacement therapy diminishes the occurrence and severity of organ dysfunction in patients with severe AP. The effect of APC on inflammatory and hemostatic parameters is also assessed.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo suppositories | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo suppositories; Assigned to Arm(s): 2
B: Arm Label: Activated protein C; Type: EXPERIMENTAL; Interventions: Drug: Activated protein C | Intervention Type: DRUG; Name: Activated protein C; Assigned to Arm(s): Activated protein C
C: Arm Label: Lipidem® (BBraun); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lipidem (Omega-3 fish oil lipid emulsion) | Arm Label: Lipofundin® MCT/LCT 20%; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lipofundin® MCT/LCT 20% | Intervention Type: DIETARY_SUPPLEMENT; Name: Lipidem (Omega-3 fish oil lipid emulsion); Assigned to Arm(s): Lipidem® (BBraun) | Intervention Type: DIETARY_SUPPLEMENT; Name: Lipofundin® MCT/LCT 20%; Assigned to Arm(s): Lipofundin® MCT/LCT 20%
D: Arm Label: Pentoxifylline; Type: EXPERIMENTAL; Interventions: Drug: Pentoxifylline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pentoxifylline; Assigned to Arm(s): Pentoxifylline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Diabetes Outcome: The Diabetes Support Project
Brief Summary: Research has shown that diabetes affects both the patient and family, and that support from family and partners helps diabetes patients manage their illness better. However, diabetes programs rarely involve the partner. The purpose of this study is to test an intervention that helps partners and patients who have type 2 diabetes better support each other. The intervention will be delivered over the telephone to reach more people. Our hypothesis is that an intervention that targets the couple has a greater effect on health and well-being of patients than one that targets the individual patient alone.


Options:
A: Arm Label: LIVE Arm; Type: EXPERIMENTAL; Interventions: Behavioral: LIVE | Arm Label: Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Website | Intervention Type: BEHAVIORAL; Name: LIVE; Assigned to Arm(s): LIVE Arm | Intervention Type: BEHAVIORAL; Name: Website; Assigned to Arm(s): Website
B: Arm Label: telecoaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telecoaching | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telecoaching; Assigned to Arm(s): telecoaching
C: Arm Label: 1 (Couples); Type: EXPERIMENTAL; Interventions: Behavioral: Telephone support and behavior change | Arm Label: 2 (Individual); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone support and behavior change | Arm Label: 3 (Control); Type: PLACEBO_COMPARATOR; Interventions: Other: Diabetes self-management education | Intervention Type: BEHAVIORAL; Name: Telephone support and behavior change; Assigned to Arm(s): 1 (Couples), 2 (Individual) | Intervention Type: OTHER; Name: Diabetes self-management education; Assigned to Arm(s): 3 (Control)
D: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults
Brief Summary: The primary objectives of this clinical trial are to determine if replacing sugar sweetened beverages with water consumption promote weight loss over 6 months in overweight adults and if replacing sugar sweetened beverages with water consumption promote greater weight loss over 6 months relative to replacement with other non-caloric sweetened beverages or control.

The secondary objective is to identify mediators and moderators of the effect of water replacement including hydration status, glucose metabolism, anthropometrics, physical activity, dietary intake and resting metabolic rate.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices
C: Arm Label: Lifestyle on-line intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle on-line intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle on-line intervention; Assigned to Arm(s): Lifestyle on-line intervention
D: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults
Brief Summary: The primary objectives of this clinical trial are to determine if replacing sugar sweetened beverages with water consumption promote weight loss over 6 months in overweight adults and if replacing sugar sweetened beverages with water consumption promote greater weight loss over 6 months relative to replacement with other non-caloric sweetened beverages or control.

The secondary objective is to identify mediators and moderators of the effect of water replacement including hydration status, glucose metabolism, anthropometrics, physical activity, dietary intake and resting metabolic rate.


Options:
A: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
B: Arm Label: Enhanced Portfolio plus structured exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced portfolio plus structured exercise | Arm Label: High fiber diet plus routine exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: High fiber diet plus routine exercise | Intervention Type: BEHAVIORAL; Name: Enhanced portfolio plus structured exercise; Assigned to Arm(s): Enhanced Portfolio plus structured exercise | Intervention Type: BEHAVIORAL; Name: High fiber diet plus routine exercise; Assigned to Arm(s): High fiber diet plus routine exercise
C: Intervention Type: OTHER; Name: Fructose; Assigned to Arm(s): N/A
D: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults
Brief Summary: The primary objectives of this clinical trial are to determine if replacing sugar sweetened beverages with water consumption promote weight loss over 6 months in overweight adults and if replacing sugar sweetened beverages with water consumption promote greater weight loss over 6 months relative to replacement with other non-caloric sweetened beverages or control.

The secondary objective is to identify mediators and moderators of the effect of water replacement including hydration status, glucose metabolism, anthropometrics, physical activity, dietary intake and resting metabolic rate.


Options:
A: Arm Label: liquid to liquid,; Type: EXPERIMENTAL; Interventions: Behavioral: liquid to liquid | Arm Label: liquid to solid,; Type: EXPERIMENTAL; Interventions: Behavioral: liquid to solid | Arm Label: solid to liquid; Type: EXPERIMENTAL; Interventions: Behavioral: solid to liquid | Arm Label: solid to solid; Type: EXPERIMENTAL; Interventions: Behavioral: solid to solid | Intervention Type: BEHAVIORAL; Name: liquid to liquid; Assigned to Arm(s): liquid to liquid, | Intervention Type: BEHAVIORAL; Name: liquid to solid; Assigned to Arm(s): liquid to solid, | Intervention Type: BEHAVIORAL; Name: solid to liquid; Assigned to Arm(s): solid to liquid | Intervention Type: BEHAVIORAL; Name: solid to solid; Assigned to Arm(s): solid to solid
B: Arm Label: Scouting curricular implementation; Type: EXPERIMENTAL; Interventions: Behavioral: Scouting Nutrition and Activity Program | Arm Label: Standard-care attentional control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard-care attentional control | Intervention Type: BEHAVIORAL; Name: Scouting Nutrition and Activity Program; Assigned to Arm(s): Scouting curricular implementation | Intervention Type: BEHAVIORAL; Name: Standard-care attentional control; Assigned to Arm(s): Standard-care attentional control
C: Arm Label: SIPsmartER, behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SipSmarter | Arm Label: Move More, behavioral intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MoveMore | Intervention Type: BEHAVIORAL; Name: SipSmarter; Assigned to Arm(s): SIPsmartER, behavioral intervention | Intervention Type: BEHAVIORAL; Name: MoveMore; Assigned to Arm(s): Move More, behavioral intervention
D: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults
Brief Summary: The primary objectives of this clinical trial are to determine if replacing sugar sweetened beverages with water consumption promote weight loss over 6 months in overweight adults and if replacing sugar sweetened beverages with water consumption promote greater weight loss over 6 months relative to replacement with other non-caloric sweetened beverages or control.

The secondary objective is to identify mediators and moderators of the effect of water replacement including hydration status, glucose metabolism, anthropometrics, physical activity, dietary intake and resting metabolic rate.


Options:
A: Arm Label: No calorie beverages; Type: EXPERIMENTAL; Interventions: Behavioral: 2 no calorie beverages per day | Arm Label: Water; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 water beverages per day | Intervention Type: BEHAVIORAL; Name: 2 no calorie beverages per day; Assigned to Arm(s): No calorie beverages | Intervention Type: BEHAVIORAL; Name: 2 water beverages per day; Assigned to Arm(s): Water
B: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
C: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices
D: Arm Label: Non Nutritive Sweetened Beverages; Type: EXPERIMENTAL; Interventions: Other: Non Nutritive Sweetened Beverages | Arm Label: Control Water Beverages; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Non Nutritive Sweetened Beverages; Assigned to Arm(s): Non Nutritive Sweetened Beverages | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control Water Beverages

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults
Brief Summary: The primary objectives of this clinical trial are to determine if replacing sugar sweetened beverages with water consumption promote weight loss over 6 months in overweight adults and if replacing sugar sweetened beverages with water consumption promote greater weight loss over 6 months relative to replacement with other non-caloric sweetened beverages or control.

The secondary objective is to identify mediators and moderators of the effect of water replacement including hydration status, glucose metabolism, anthropometrics, physical activity, dietary intake and resting metabolic rate.


Options:
A: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices
D: Intervention Type: BEHAVIORAL; Name: Weight reduction, Resistance training, Aerobic exercise training, Control; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC
Brief Summary: The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants. Half of the participants will receive chemotherapy (pemetrexed/cisplatin) followed by an oral anti-cancer agent (gefitinib) and the other half of the participants will receive only the oral anti-cancer agent (gefitinib).


Options:
A: Arm Label: Alimta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed (Alimta) | Arm Label: IRESSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib (IRESSA) | Intervention Type: DRUG; Name: Pemetrexed (Alimta); Assigned to Arm(s): Alimta | Intervention Type: DRUG; Name: Gefitinib (IRESSA); Assigned to Arm(s): IRESSA
B: Arm Label: Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib, Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Gefitinib, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gefitinib, Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
D: Arm Label: Pemetrexed + Cisplatin + Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib

Answer: D